Beyond THC & CBD: A Look at the Other Cannabinoids
Jeremy Martin
February 10th, 2017
Policy, Top News
With recreational and medical cannabis dispensaries now numbering in the thousands nationwide, consumers and patients alike are finding themselves inundated with strain and brand options at a rate never before seen. Plants are being selected and bred to treat a range of symptoms from the daily inconvenience of headaches or lethargy up to the life-altering such as Chron’s Disease and seizure disorder.
Cannabinoids, the active chemical compound found in marijuana is what dictates how effective one strain will be over another in treating certain symptoms. Cannabis has long been bred for high THC or Delta(9)-tetrahydrocannabinol, a chemical compound that creates a psychoactive effect in humans but acts as an anti-bacterial and pesticide for the plant itself. Beyond THC, the second most prevalent cannabinoid is Cannabidiol or CBD. Lately, patients, researchers, and doctors alike have been discovering a multitude of uses for this compound including fighting seizure disorder, calming nausea, lowering pain and decreasing inflammation. However, there are currently 111 known cannabinoids with the vast majority seeing only diminutive research, though they all may play vital roles in fighting illness or simply allowing a user to better enjoy themselves.
Much of the public’s focus has been on ‘local cannabis’ industries, IE the sale of recreational buds at a neighborhood shop, but a great deal of cannabinoid research is being conducted by the medical technology and pharmaceutical industries. Edibles, Zoots, tinctures and other noncombustible cannabis delivery systems are readily available and the pharmaceutical industry is now slowly rolling out organic and synthetic cannabinoid-based medications. Sativex from GW Pharmaceuticals, for example, is an oral spray derived from a natural THC and CBD blend which is being used as a remedy for patients with severe to moderate pain from multiple sclerosis. The drug launched in the UK in 2010 and was soon available in nearly a dozen countries around the globe, but is not currently available in the United States. The majority of cannabinoid-based drugs such as Caymen Chemical’s HU 331 are still only available for research purposes and not scheduled for distribution to the general public. HU 331, a synthetic compound based on CB1 (Central Cannabinoid) and CB2 (Peripheral Cannabinoid) may one day be used to treat a range of symptoms from weight loss and memory loss to muscle spasms and inflammation.
The pharmaceutical cannabinoid market, with its heavy reliance on synthesized medicine continues to lag dramatically behind the recreational and medical cannabis market in terms of both overall sales and profits. Though as R&D continues, and new drugs hit the market, the pharmaceutical footprint is poised to see substantial growth over the next few years and beyond. The experts at statista.com go so far as to predict that the cannabis biotech/pharmaceutical sector could represent 10% of the overall specialty pharmaceutical market over the next five years, suggesting a market size of at least $20 billion. Whereas legal, non-pharmaceutical cannabis has already passed the $6 billion per year mark and will likely, according to Bloomberg, surpass $50 billion by 2026.
Despite new research into a variety of cannabinoids, if these predictions are to be trusted, the reason for big pharma’s potential growth (and that of the overall cannabis industry) will more than likely revolve around two things: THC and CBD.
According to Joel Anderson, senior editor for Equities.com, “Cannabis contains over (100) different identifiable cannabinoids which have varied effects and could potentially be developed into treatments. However, two, in particular, are of note; THC, which provides most of the cannabis’ psychoactive effects, and cannabidiol, which has been the center of much of the most exciting medical research surrounding the endocannabinoid system.”
With that in mind, there is still plenty of growth potential for lesser known cannabinoids. CBC or Cannabichromene, for example, is a known anti-inflammatory that may also posses anti-fungal and anti-depressant characteristics. CBN is an interesting compound as it is not found in living or freshly processes cannabis plants. This cannabinoid is only found in processed marijuana that has been left to dry. CBN may be a mild antibiotic and anti-asthmatic, but most noticeably it is a quite powerful appetite stimulant and may, in fact, be the primary cannabinoid behind the dreaded ‘munchies.’
As of The Weed Blog explains “Each cannabinoid can provide varying levels of medical benefit, and research has shown that each cannabinoid works the best when they are combined. It’s called the ‘entourage effect’.”
That being said, cannabinoid R&D is still in its infancy, so holding your breath for a nonTHC or CBD based pharmaceutical to shortly appear on the market is not advised. However, initial research is already showing that the lesser known cannabinoids may play a vital role in supplementing the medical possibilities of both THC and CBD and may, in the future provide a range of therapeutic and medicinal products in their own right.
To learn more about cannabinoid research, sign-up for our free newsletter using the form to the right.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Jeremy Martin
Jeremy Martin is a Seattle-based writer reporting on coffee, craft beer, music, college sports, cannabis and business for a variety of publications. A competitive disc golfer and avid sandwich maker, he graduated from Western Michigan University in 2009. He and his wife are expecting their first child in July.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Tom Zuber is Zuber Lawler & Del Duca’s Managing Partner. He has a degree with highest honors in biomedical engineering and has advised some of the most iconic companies in the world on their patent and trademark portfolios. He is at the cutting edge of cannabis patent and trademark law. He holds degrees from Harvard University and Columbia Law […]
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
IONIC BRANDS is a national cannabis holdings company based in Washington, led by a team of successful entrepreneurs.
CalEthos Inc. (OTC Pink: BUUZ) is building a chain of large-format retail store and event center facilities to serve the needs of the rapidly growing Southern California cannabis market.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
